Panobinostat (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Panobinostat" in English language version.

refsWebsite

Global rank English rank

10nih.gov

4^th place

7doi.org

2^nd place

5web.archive.org

1^st place

3clinicaltrials.gov

5,225^th place

4,062^nd place

3fda.gov

447^th place

338^th place

2europa.eu

68^th place

117^th place

2worldcat.org

5^th place

1tga.gov.au

3,984^th place

2,622^nd place

1nature.com

234^th place

397^th place

1semanticscholar.org

11^th place

8^th place

1federalregister.gov

2,474^th place

1,469^th place

1pagepress.org

low place

1telegraph.co.uk

30^th place

24^th place

1cancertherapyadvisor.com

low place

1mayoclinic.org

1,610^th place

1,279^th place

cancertherapyadvisor.com

Hoffman J (May 2016). "Panobinostat May Be Active in Select Patients With Refractory DLBCL". CancerTherapyAdvisor.com. Archived from the original on 8 August 2016. Retrieved 23 May 2016.

clinicaltrials.gov

Clinical trial number NCT00425555 for "Study of Oral LBH589 in Adult Patients With Refractory Cutaneous T-Cell Lymphoma" at ClinicalTrials.gov
"Studies found for LBH-589". ClinicalTrials.gov.
Clinical trial number NCT01680094 for "Safety and Effect of The HDAC Inhibitor Panobinostat on HIV-1 Expression in Patients on Suppressive HAART (CLEAR)" at ClinicalTrials.gov

doi.org

Revill P, Mealy N, Serradell N, Bolos J, Rosa E (2007). "Panobinostat". Drugs of the Future. 32 (4): 315. doi:10.1358/dof.2007.032.04.1094476.
Table 3: Select epigenetic inhibitors in various stages of development Archived 18 April 2016 at the Wayback Machine from Mack GS (December 2010). "To selectivity and beyond". Nature Biotechnology. 28 (12): 1259–66. doi:10.1038/nbt.1724. PMID 21139608. S2CID 11480326.
Rasmussen TA, Tolstrup M, Brinkmann CR, Olesen R, Erikstrup C, Solomon A, et al. (October 2014). "Panobinostat, a histone deacetylase inhibitor, for latent-virus reactivation in HIV-infected patients on suppressive antiretroviral therapy: a phase 1/2, single group, clinical trial". The Lancet. HIV. 1 (1): e13-21. doi:10.1016/S2352-3018(14)70014-1. PMID 26423811.
Garbes L, Riessland M, Hölker I, Heller R, Hauke J, Tränkle C, et al. (October 2009). "LBH589 induces up to 10-fold SMN protein levels by several independent mechanisms and is effective even in cells from SMA patients non-responsive to valproate". Human Molecular Genetics. 18 (19): 3645–58. doi:10.1093/hmg/ddp313. PMID 19584083.
Tate CR, Rhodes LV, Segar HC, Driver JL, Pounder FN, Burow ME, Collins-Burow BM (May 2012). "Targeting triple-negative breast cancer cells with the histone deacetylase inhibitor panobinostat". Breast Cancer Research. 14 (3): R79. doi:10.1186/bcr3192. PMC 3446342. PMID 22613095.
Rasmussen TA, Schmeltz Søgaard O, Brinkmann C, Wightman F, Lewin SR, Melchjorsen J, et al. (May 2013). "Comparison of HDAC inhibitors in clinical development: effect on HIV production in latently infected cells and T-cell activation". Human Vaccines & Immunotherapeutics. 9 (5): 993–1001. doi:10.4161/hv.23800. PMC 3899169. PMID 23370291.
Grasso CS, Tang Y, Truffaux N, Berlow NE, Liu L, Debily MA, et al. (June 2015). "Functionally defined therapeutic targets in diffuse intrinsic pontine glioma". Nature Medicine. 21 (6): 555–9. doi:10.1038/nm.3855. PMC 4862411. PMID 25939062.

europa.eu

ema.europa.eu

"Farydak EPAR". European Medicines Agency. 17 September 2018. Retrieved 22 October 2022.
"Farydak product details". European Medicines Agency. 17 September 2018. Archived from the original on 20 June 2018. Retrieved 1 February 2017.

fda.gov

"Drug Trials Snapshot: Farydak (panobinostat)". U.S. Food and Drug Administration (FDA). 30 July 2020. Retrieved 22 October 2022.
"Withdrawn Oncology /Hematologic Malignancies Accelerated Approvals". U.S. Food and Drug Administration (FDA). 1 June 2022. Retrieved 22 October 2022.

accessdata.fda.gov

"Farydak Drug Approval Package". U.S. Food and Drug Administration (FDA). 17 March 2015. Retrieved 22 October 2022.

federalregister.gov

"Secura Bio, Inc.; Withdrawal of Approval of New Drug Application for Farydak (panobinostat) Capsules, 10 Milligrams, 15 Milligrams, and 20 Milligrams". Federal Register. 24 March 2022. Retrieved 22 October 2022.

mayoclinic.org

"Mayo Clinic Researchers Formulate Treatment Combination Lethal To Pancreatic Cancer Cells". The Mayo Clinic. Archived from the original on 20 February 2012.

nature.com

Table 3: Select epigenetic inhibitors in various stages of development Archived 18 April 2016 at the Wayback Machine from Mack GS (December 2010). "To selectivity and beyond". Nature Biotechnology. 28 (12): 1259–66. doi:10.1038/nbt.1724. PMID 21139608. S2CID 11480326.

nih.gov

pubmed.ncbi.nlm.nih.gov

Table 3: Select epigenetic inhibitors in various stages of development Archived 18 April 2016 at the Wayback Machine from Mack GS (December 2010). "To selectivity and beyond". Nature Biotechnology. 28 (12): 1259–66. doi:10.1038/nbt.1724. PMID 21139608. S2CID 11480326.
Rasmussen TA, Tolstrup M, Brinkmann CR, Olesen R, Erikstrup C, Solomon A, et al. (October 2014). "Panobinostat, a histone deacetylase inhibitor, for latent-virus reactivation in HIV-infected patients on suppressive antiretroviral therapy: a phase 1/2, single group, clinical trial". The Lancet. HIV. 1 (1): e13-21. doi:10.1016/S2352-3018(14)70014-1. PMID 26423811.
Garbes L, Riessland M, Hölker I, Heller R, Hauke J, Tränkle C, et al. (October 2009). "LBH589 induces up to 10-fold SMN protein levels by several independent mechanisms and is effective even in cells from SMA patients non-responsive to valproate". Human Molecular Genetics. 18 (19): 3645–58. doi:10.1093/hmg/ddp313. PMID 19584083.
Tate CR, Rhodes LV, Segar HC, Driver JL, Pounder FN, Burow ME, Collins-Burow BM (May 2012). "Targeting triple-negative breast cancer cells with the histone deacetylase inhibitor panobinostat". Breast Cancer Research. 14 (3): R79. doi:10.1186/bcr3192. PMC 3446342. PMID 22613095.
Rasmussen TA, Schmeltz Søgaard O, Brinkmann C, Wightman F, Lewin SR, Melchjorsen J, et al. (May 2013). "Comparison of HDAC inhibitors in clinical development: effect on HIV production in latently infected cells and T-cell activation". Human Vaccines & Immunotherapeutics. 9 (5): 993–1001. doi:10.4161/hv.23800. PMC 3899169. PMID 23370291.
Grasso CS, Tang Y, Truffaux N, Berlow NE, Liu L, Debily MA, et al. (June 2015). "Functionally defined therapeutic targets in diffuse intrinsic pontine glioma". Nature Medicine. 21 (6): 555–9. doi:10.1038/nm.3855. PMC 4862411. PMID 25939062.

ncbi.nlm.nih.gov

Tate CR, Rhodes LV, Segar HC, Driver JL, Pounder FN, Burow ME, Collins-Burow BM (May 2012). "Targeting triple-negative breast cancer cells with the histone deacetylase inhibitor panobinostat". Breast Cancer Research. 14 (3): R79. doi:10.1186/bcr3192. PMC 3446342. PMID 22613095.
Rasmussen TA, Schmeltz Søgaard O, Brinkmann C, Wightman F, Lewin SR, Melchjorsen J, et al. (May 2013). "Comparison of HDAC inhibitors in clinical development: effect on HIV production in latently infected cells and T-cell activation". Human Vaccines & Immunotherapeutics. 9 (5): 993–1001. doi:10.4161/hv.23800. PMC 3899169. PMID 23370291.
Grasso CS, Tang Y, Truffaux N, Berlow NE, Liu L, Debily MA, et al. (June 2015). "Functionally defined therapeutic targets in diffuse intrinsic pontine glioma". Nature Medicine. 21 (6): 555–9. doi:10.1038/nm.3855. PMC 4862411. PMID 25939062.

dailymed.nlm.nih.gov

"Farydak- panobinostat capsule". DailyMed. 27 July 2021. Retrieved 22 October 2022.

pagepress.org

Prince HM, Prince M (2009). "Panobinostat (LBH589): a novel pan-deacetylase inhibitor with activity in T cell lymphoma". Hematology Meeting Reports. 3 (1). Parkville, Australia: Peter MacCallum Cancer Centre and University of Melbourne: 33–38.

semanticscholar.org

api.semanticscholar.org

Table 3: Select epigenetic inhibitors in various stages of development Archived 18 April 2016 at the Wayback Machine from Mack GS (December 2010). "To selectivity and beyond". Nature Biotechnology. 28 (12): 1259–66. doi:10.1038/nbt.1724. PMID 21139608. S2CID 11480326.

telegraph.co.uk

Simons J (27 April 2013). "Scientists on brink of HIV cure". The Telegraph. Archived from the original on 27 April 2013.

tga.gov.au

"Prescription medicines: registration of new chemical entities in Australia, 2016". Therapeutic Goods Administration (TGA). 21 June 2022. Retrieved 10 April 2023.

web.archive.org

Table 3: Select epigenetic inhibitors in various stages of development Archived 18 April 2016 at the Wayback Machine from Mack GS (December 2010). "To selectivity and beyond". Nature Biotechnology. 28 (12): 1259–66. doi:10.1038/nbt.1724. PMID 21139608. S2CID 11480326.
"Farydak product details". European Medicines Agency. 17 September 2018. Archived from the original on 20 June 2018. Retrieved 1 February 2017.
Simons J (27 April 2013). "Scientists on brink of HIV cure". The Telegraph. Archived from the original on 27 April 2013.
Hoffman J (May 2016). "Panobinostat May Be Active in Select Patients With Refractory DLBCL". CancerTherapyAdvisor.com. Archived from the original on 8 August 2016. Retrieved 23 May 2016.
"Mayo Clinic Researchers Formulate Treatment Combination Lethal To Pancreatic Cancer Cells". The Mayo Clinic. Archived from the original on 20 February 2012.

worldcat.org

Rajkumar SV (2018). "Multiple Myeloma". In Hensley ML, Milowsky MI, Rajkumar SV, Schuetze SM (eds.). ASCO-SEP : Medical Oncology Self-Evaluation Program (7th ed.). Alexandria, VA: American Society of Clinical Oncology. ISBN 978-0-9983747-4-1. OCLC 1080368315.

search.worldcat.org

Rajkumar SV (2018). "Multiple Myeloma". In Hensley ML, Milowsky MI, Rajkumar SV, Schuetze SM (eds.). ASCO-SEP : Medical Oncology Self-Evaluation Program (7th ed.). Alexandria, VA: American Society of Clinical Oncology. ISBN 978-0-9983747-4-1. OCLC 1080368315.